Orelabrutinib + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Secondary Progressive Multiple Sclerosis

Conditions

Secondary Progressive Multiple Sclerosis

Trial Timeline

Mar 1, 2026 → Jul 1, 2030

NCT ID

NCT07299019

About Orelabrutinib + Placebo

Orelabrutinib + Placebo is a phase 3 stage product being developed by Zenas BioPharma for Secondary Progressive Multiple Sclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07299019. Target conditions include Secondary Progressive Multiple Sclerosis.

What happened to similar drugs?

6 of 20 similar drugs in Secondary Progressive Multiple Sclerosis were approved

Approved (6) Terminated (0) Active (14)

🔄KHK7580Kyowa KirinPhase 3

✅Cinacalcet HClKyowa KirinApproved

🔄KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3

🔄paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07299019	Phase 3	Recruiting	Mar 1, 2026	Jul 1, 2030	Secondary Progressive Multiple Sclerosis
NCT07067463	Phase 3	Recruiting	Dec 1, 2025	Jul 1, 2030	Multiple Sclerosis (MS) Primary Progressive

Competing Products

20 competing products in Secondary Progressive Multiple Sclerosis

See all competitors

Product	Company	Stage	Hype Score
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	38
KHK7580	Kyowa Kirin	Phase 1	29
KHK7580	Kyowa Kirin	Phase 3	40
KHK7580	Kyowa Kirin	Phase 3	40
Cinacalcet HCl	Kyowa Kirin	Approved	43
KHK7580 + Cinacalcet Hydrochloride	Kyowa Kirin	Phase 3	40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493	Kyowa Kirin	Phase 2	35
dirucotide + Placebo	Eli Lilly	Phase 2/3	38
dirucotide	Eli Lilly	Phase 2/3	30
Paricalcitol + Calcitriol	AbbVie	Pre-clinical	18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo	AbbVie	Phase 3	40
Paricalcitol + Calcifediol	AbbVie	Approved	43
Paricalcitol + Darbepoetin alfa	AbbVie	Approved	43
Birabresib Dose 20 mg	Merck	Phase 1	21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	47
Ranibizumab	Novartis	Approved	43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	43